Gina Mauro

Adavosertib demonstrated a 65% risk reduction in disease progression and death for patients with TP53-/RAS-mutant metastatic colorectal cancer following first-line chemotherapy.

Patients with stage II to IIIA non–small cell lung cancer experienced an improvement in disease-free survival and time to locoregional and distant relapse after being treated with adjuvant atezolizumab.

Data presented at 2021 ESMO show that nivolumab plus chemotherapy improves survival outcomes in certain patients with frontline gastrointestinal cancers, but not nivolumab plus ipilimumab.

Patients with HER2-mutated non–small cell lung cancer derived robust and long-lasting responses from fam-trastuzumab deruxtecan-nxki.

Updated results of DESTINY-Gastric02 trial show antitumor response with trastuzumab deruxtecan in patients with in certain patients with HER2-positive gastric/gastroesophageal junction.

An analysis of patients with prostate cancer treated with immune checkpoint blockade indicated that microsatellite instability and mismatch repair may be indicative of response.

Although the addition of carboplatin to neoadjuvant paclitaxel followed by cyclophosphamide helped to improve outcomes for those with treatment-naïve triple-negative breast cancer, the addition of veliparib did not have an impact on pathologic complete response or event-free survival.

Patients with previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma appeared to benefit from treatment with pirtobrutinib.

Patients with relapsed/refractory multiple myeloma who were treated with the recommended phase 2 dose of talquetamab experienced positive clinical activity.

Strong response rates were observed with pirtobrutinib across dose levels to treat patients with chronic lymphocytic leukemia and small lymphocytic lymphoma ion a phase 1/2 study.

The phase 3 POSEIDON trial indicated that patients with metastatic non–small cell lung cancer who were treated with first-line durvalumab and chemotherapy with or without tremelimumab experienced a statistically significant survival benefit.

Previously platinum-treated patients with EGFR exon 20 insertion mutation–positive non–small cell lung cancer saw clinical activity with mobocertinib regardless of prior PD-1/PD-L1 inhibitor history.

CYNK-001, a human placental hematopoietic stem cell–derived natural killer cell infusion, will now be tested in an expanded population following promising results in a phase 1 trial.

Data presented at 2021 ASCO indicated that chimeric antigen receptor therapy with ALLO-501A plus ALLO-647 lymphodepletion showed promise in patients with relapsed/refractory large B-cell lymphoma.

Pimitespib significantly improved progression-free survival while prolonging overall survival compared with placebo to treat patients with advanced gastrointestinal stromal tumor.

Clinical activity of the combination of pertuzumab and trastuzumab in seen in patients with ERBB2/ERBB3 overexpressing uterine cancers.

Nivolumab monotherapy, or in combination with ipilimumab, continued to demonstrate durable improvements in overall survival compared with ipilimumab alone in patients with previously untreated advanced melanoma.

While selumetinib was well-tolerated, it did not drive objective responses.

Patients with pretreated KRAS p.G12C–mutated NSCLC experienced a continued durable clinical benefit with sotorasib.

Regardless of primary tumor site or disease stage, avelumab maintenance was able to elicit overall survival benefit versus best supportive care for platinum-treated urothelial cancer.

Data from the KEYNOTE-564 trial presented at ASCO indicate benefit of pembrolizumab therapy in patients with clear cell renal cell carcinoma who were receiving therapy in the adjuvant setting.

In a phase 1 study of the innate cell engager AFM13, all 4 patients with CD30-positive, relapsed/refractory Hodgkin lymphoma treated with the therapy achieved at least a partial response.

The selective MCL-1 inhibitor AMG 176 plus gilteritinib as a combination treatment synergistically targeted preclinical models of FLT3 internal tandem duplication–mutated acute myeloid leukemia.

Nivolumab in combination with paclitaxel showed clinical activity and a manageable safety profile when used as second-line therapy for patients with Epstein-Barr virus–related, microsatellite instability–high/mismatch repair deficient or PD-L1–positive advanced gastric cancer.

The early results showed that voruciclib led to a rapid decrease in the phosphorylation of proteins that promote MYC transcription and quickly decreases phosphorylation of MYC protein on Serine 62 (Ser62), which is a site implicated in stabilizing MYC in KRAS-mutant cancers.

Patients with metastatic renal cell carcinoma and brain metastases showed significant intracranial and extracranial responses with cabozantinib use.

Avelumab plus best supportive care as frontline maintenance therapy produced a favorable benefit-risk balance for Japanese patients with advanced urothelial cancer who did not progress on first-line chemotherapy.

Patients with KRAS G12C–mutated advanced non–small cell lung cancer show antitumor response and survival benefit with the KRAS G12C inhibitor sotorasib, formerly AMG 510.

A real-world study enlightens to the importance of NRG1 fusions in non–small cell lung cancer and provides possible steps forward.

Overall survival benefits were noted when ivosidenib tablets were used in previously treated patients with IDH1-mutant cholangiocarcinoma when compared against placebo, according to a phase 3 trial.